Anaconda Biomed Raises $56M for Stroke Tech

Anaconda Biomed, a medical technology firm focused on innovative neurovascular treatments, has successfully closed a significant $56 million funding round. This capital infusion is earmarked to propel the company's next phase of development, including the completion of its pivotal IDE ATHENA study, further product refinement, and the pursuit of global regulatory approvals for its novel thrombectomy catheter portfolio.

The investment was spearheaded by Omega Funds, with substantial participation from new investor Fondo de Coinversión de España (FOCO), managed by COFIDES. Existing backers, including Asabys (through Sabadell Asabys I), Ysios Capital, and CDTI (via its SICC Innvierte program), also demonstrated continued confidence by reinvesting in the company.

The funds will be critical in advancing Anaconda's proprietary Funnel Catheter platform, a technology designed to enhance clot capture, minimize embolic complications, and maximize cerebral reperfusion in stroke patients. The ongoing IDE ATHENA trial, a randomized study involving 327 participants, is a key focus, aiming to validate the safety and efficacy of the ANA Funnel Catheter. This advancement is particularly relevant in the global ischemic stroke market, which accounts for millions of deaths annually and sees mechanical thrombectomy procedures performed on hundreds of thousands of patients worldwide.

“This financing empowers us to accelerate our mission of improving acute stroke treatment outcomes, ultimately aiming to reduce disability and mortality associated with large vessel occlusive disease,” stated Trent Reutiman, CEO of Anaconda Biomed. “The backing from this distinguished group of investors underscores the growing belief in our technological capabilities and ensures we have the resources to meet our clinical and regulatory milestones.”

Claudio Nessi, Managing Director at Omega Funds, commented on the investment, highlighting Anaconda's potential in the expanding ischemic stroke market. “Anaconda offers a next-generation solution for a critical unmet need. Their product pipeline holds the promise of better patient outcomes globally. With a robust team led by Trent Reutiman, we believe Anaconda possesses the unique technology and resources to make a significant impact in the highly competitive interventional neurovascular device sector.”

Anaconda's strategic move includes establishing a state-of-the-art manufacturing facility near Barcelona. This direct control over key development and production processes is expected to foster agile, efficient, and iterative product line expansion, while also generating valuable intellectual property around their core technology. The company's product suite, designed to complement the Funnel Catheter, includes stent retrievers, introducers, and guidewires, paving the way for broader clinical applications.